Nascent Pharma Holdings Inc (NASC) Stock Price, Trades & News

Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	16.86
	9-Day RSI	28.19
	14-Day RSI	35.36
	3-1 Month Momentum %	24.17
	6-1 Month Momentum %	-6.88
	12-1 Month Momentum %	-0.67

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History
	FCF Margin %	23.81
	OCF Margin %	23.81

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	EV-to-Forward-Revenue	0.64

GF Value™

NASC

Warning Signs

Warning! GuruFocus detected issues with NASC. Try a 7-Day Free Trial to check it out.

Nascent Pharma Holdings Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Nascent Pharma Holdings Inc Stock Events

Financials Calendars

Event	Date	Price ($)
0.066667:1 Stock Split	2022-02-14	8.10 (+5.88%)
0.003333:1 Stock Split	2020-03-06	34.20 (-15.56%)
0.1:1 Stock Split	2013-06-04	688.57 (+0.00%)

Show

Entries

Guru Commentaries on OTCPK:NASC

No articles.

Press Release

	Subject	Date
	Can B Corp.'s Pure Health Products Awarded NSF's GMP Certification	2021-12-30
	Can B Corp. Reports 316% Revenue Growth to a Quarterly Revenue Record of $1.9 Million for its Third Quarter 2021	2021-11-05
	Can B Corp. to Produce 13,000 Liters of Delta-8 and Other Isomers with Potential $10 Million Revenue	2021-09-15
	Can B Corp. Secures Lease for 300,000 Square Foot Facility in McMinnville, Tennessee	2021-08-25
	Can B Corp. Closes Acquisition of Assets from Music City Botanicals to Strengthen its Vertical Processing Capabilities	2021-08-19
	Can B Corp. Reports 96% Revenue Growth for Its Second Quarter 2021	2021-08-18
	Can B Corp. Closes Acquisition of Assets from TWS Pharma in CO to Significantly Expand Capabilities in Converting Hemp Biomass to Isolate Used in our CBD and Isomer Product Lines	2021-08-17
	Can B Corp. Partners with Group of Professional Hollywood Stuntmen and World Champion Action Sports Athletes for CBD Products, Expects to Launch New CBD Brand by End of Summer	2021-07-29
	Can B Corp Announces First Quarter 2021 Results	2021-05-22
	Can B Corp. Enters the Industrial Hemp Business	2021-05-12

10/Page

Articles on Nascent Pharma Holdings Inc

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.